Antimicrobial resistance already creates measurable harm in hospitals. WHO estimates AMR caused 1.27 million deaths in 2019, and CDC projects antibiotic resistant infections could reach 10 million deaths per year worldwide by 2050. Studies also link resistant infections to higher mortality and longer stays, while stewardship and faster diagnostics reduce the time patients spend on ineffective treatment.
Key Takeaways
- In 2019, the analysis estimated 35.7 million AMR-associated DALYs due to bacterial resistance
- WHO estimates that AMR caused 1.27 million deaths in 2019
- CDC’s 2019 AR Threats report projected that by 2050, antibiotic-resistant infections could cause 10 million deaths annually worldwide and cost $100 trillion (global economic estimate referenced by CDC)
- A 2022 systematic review reported that patients infected with multidrug-resistant organisms had a higher risk of mortality than those with non-resistant infections (pooled effect reported)
- In ECDC/EMA 2023 antimicrobial resistance surveillance report, 35,000 hospital bloodstream infections due to AMR organisms were estimated in Europe (reported scale for serious AMR)
- In US hospitals, 1 in 3 antibiotic prescriptions is estimated to be inappropriate (CDC estimate)
- CDC reported that 2.6 million antibiotic prescriptions were given to residents of nursing homes in 2018 (HCRS data; stewardship reporting)
- In a 2023 study, antimicrobial stewardship interventions in hospitals were associated with a 13% reduction in antibiotic consumption (meta-analysis pooled change)
- A 2021 meta-analysis estimated that rapid diagnostics for bloodstream infections reduced antibiotic exposure by 1.2 days on average (pooled estimate)
- A 2022 randomized trial reported that rapid molecular testing shortened time to optimal therapy by 1 day (reported trial metric)
- In a 2020 evaluation, MALDI-TOF mass spectrometry reduced turnaround time for pathogen identification by 24 hours on average compared with conventional methods (reported operational metric)
- In 2023, the global antimicrobial susceptibility testing market was valued at $2.8 billion and projected to grow to $4.4 billion by 2030 (vendor/market research estimate)
- In 2023, the global antimicrobial resistance testing market was valued at $3.2 billion and projected to grow to $5.5 billion by 2030 (market research estimate)
- In 2022, the global antibiotics market size was estimated at $43 billion (context for stewardship and AMR; vendor market estimate)
- OECD estimated that antimicrobial resistance could reduce global GDP by 3.8% by 2050 in a policy-inaction scenario (economic impact estimate)
AMR kills about 1.27 million people yearly and stewardship plus rapid diagnostics can cut infections and antibiotic use.
Related reading
01 · Category
Burden & Outcomes8 stats
01
In 2019, the analysis estimated 35.7 million AMR-associated DALYs due to bacterial resistance
02
WHO estimates that AMR caused 1.27 million deaths in 2019
03
CDC’s 2019 AR Threats report projected that by 2050, antibiotic-resistant infections could cause 10 million deaths annually worldwide and cost $100 trillion (global economic estimate referenced by CDC)
04
In a 2023 study, AMR infections increased 30-day mortality by 2.0 percentage points on average vs susceptible infections (reported absolute difference)
05
In a 2022 meta-analysis, multidrug-resistant infections were associated with an overall mortality odds ratio of about 2.0 (pooled)
06
In a 2021 systematic review, resistant bloodstream infections were associated with a pooled hazard ratio for mortality of 1.8
07
In a 2020 prospective cohort, patients with carbapenem-resistant Enterobacterales had an in-hospital mortality rate of 40% (reported cohort outcome)
08
In a 2018 study of MRSA, MRSA bacteremia had a mortality rate of 20% in the study cohort (reported outcome)
Interpretation
Burden & Outcomes Interpretation
The burden of antimicrobial resistance is substantial and worsening, with 1.27 million deaths in 2019 and tens of millions of AMR-associated DALYs, while studies consistently show worse outcomes such as a 2.0 percentage point higher 30-day mortality for resistant infections and roughly double the risk of death for multidrug-resistant and resistant bloodstream infections.
02 · Category
Surveillance & Resistance Rates2 stats
01
A 2022 systematic review reported that patients infected with multidrug-resistant organisms had a higher risk of mortality than those with non-resistant infections (pooled effect reported)
02
In ECDC/EMA 2023 antimicrobial resistance surveillance report, 35,000 hospital bloodstream infections due to AMR organisms were estimated in Europe (reported scale for serious AMR)
Interpretation
Surveillance & Resistance Rates Interpretation
In the surveillance data, multidrug-resistant infections are linked to higher mortality and Europe’s 2023 AMR report estimates about 35,000 hospital bloodstream infections from AMR organisms, underscoring that resistance is not just rising in surveillance but is producing serious real world outcomes.
03 · Category
Usage & Stewardship Metrics4 stats
01
In US hospitals, 1 in 3 antibiotic prescriptions is estimated to be inappropriate (CDC estimate)
02
CDC reported that 2.6 million antibiotic prescriptions were given to residents of nursing homes in 2018 (HCRS data; stewardship reporting)
03
In a 2023 study, antimicrobial stewardship interventions in hospitals were associated with a 13% reduction in antibiotic consumption (meta-analysis pooled change)
04
A 2022 meta-analysis found that antimicrobial stewardship programs reduced the incidence of C. difficile infection by about 35% (pooled reduction)
Interpretation
Usage & Stewardship Metrics Interpretation
Across usage and stewardship metrics, the evidence points to measurable impact: CDC estimates suggest 1 in 3 antibiotic prescriptions in US hospitals may be inappropriate, while stewardship efforts are linked to a 13% reduction in hospital antibiotic consumption and about a 35% drop in C. difficile incidence.
04 · Category
Diagnostics & Innovation Uptake4 stats
01
A 2021 meta-analysis estimated that rapid diagnostics for bloodstream infections reduced antibiotic exposure by 1.2 days on average (pooled estimate)
02
A 2022 randomized trial reported that rapid molecular testing shortened time to optimal therapy by 1 day (reported trial metric)
03
In a 2020 evaluation, MALDI-TOF mass spectrometry reduced turnaround time for pathogen identification by 24 hours on average compared with conventional methods (reported operational metric)
04
In a 2021 cohort study, rapid susceptibility testing reduced time to appropriate therapy by 1.6 days (reported clinical workflow metric)
Interpretation
Diagnostics & Innovation Uptake Interpretation
Across recent evidence, diagnostics innovation is clearly speeding clinical decision making, with rapid testing cutting time to better treatment by about 1 to 1.6 days on average and MALDI-TOF reducing pathogen identification turnaround by 24 hours, showing strong uptake impact under the Diagnostics and Innovation Uptake category.
05 · Category
Market Size9 stats
01
In 2023, the global antimicrobial susceptibility testing market was valued at $2.8 billion and projected to grow to $4.4 billion by 2030 (vendor/market research estimate)
02
In 2023, the global antimicrobial resistance testing market was valued at $3.2 billion and projected to grow to $5.5 billion by 2030 (market research estimate)
03
In 2022, the global antibiotics market size was estimated at $43 billion (context for stewardship and AMR; vendor market estimate)
04
In 2023, the US antimicrobial resistance market for diagnostics and susceptibility testing was estimated to exceed $1.0 billion (market research estimate)
05
In 2024, the global antimicrobial resistance (AMR) diagnostics market was projected by some analysts to exceed $3.0 billion by 2029 (analyst projection)
06
In 2023, the global market for rapid antimicrobial susceptibility testing instruments was estimated at $1.6 billion (market estimate)
07
In 2023, the global antimicrobial stewardship market was estimated at $3.9 billion and expected to grow to $7.2 billion by 2030 (market estimate)
08
In 2022, the global antibiotic resistance testing market (products including consumables and instruments) was valued at $2.3 billion (market estimate)
09
In 2021, the global antibiotics market exceeded $50 billion in revenue (market estimate)
Interpretation
Market Size Interpretation
For the Market Size category, the data shows strong growth momentum across the AMR testing and diagnostics ecosystem, with global susceptibility testing rising from $2.8 billion in 2023 to $4.4 billion by 2030 and AMR testing growing from $3.2 billion in 2023 to $5.5 billion by 2030.
06 · Category
Investment & Costs4 stats
01
OECD estimated that antimicrobial resistance could reduce global GDP by 3.8% by 2050 in a policy-inaction scenario (economic impact estimate)
02
A 2016 review estimated the global economic cost of AMR could reach $100 trillion by 2050 (forecast in peer-reviewed publication)
03
In 2019, the global annual productivity loss due to AMR was estimated at $1 trillion (economic impact analysis estimate)
04
A 2017 study estimated that AMR could reduce global life expectancy by about 0.4 years on average by 2050 (mortality/life expectancy impacts)
Interpretation
Investment & Costs Interpretation
From an investment and costs perspective, antimicrobial resistance represents a compounding economic threat with OECD estimating a 3.8% hit to global GDP by 2050 under policy inaction, alongside forecasts rising to $100 trillion in cumulative costs and $1 trillion in annual productivity losses, even as reduced life expectancy of about 0.4 years by 2050 underscores why these costs are not just financial but systemic.
More related reading
07 · Category
Cost Analysis7 stats
01
A 2019 meta-analysis reported healthcare costs were higher by about $6,500per AMR case compared to non-resistant infections (pooled incremental cost)
02
In a US claims analysis, resistant infections increased total healthcare costs by $29,000per case compared with susceptible infections (reported incremental cost)
03
A 2021 cohort study found that carbapenem-resistant infections increased ICU days by 2.3 days on average (reported difference)
04
In the UK, NICE estimated that stewardship and infection prevention measures can avert costs by reducing AMR-related complications (quantified in an impact assessment)
05
In a 2022 costing model, implementing infection prevention and control reduced AMR-related costs by 15% in the modelled hospitals (scenario result)
06
In a 2020 health technology assessment, rapid molecular diagnostics had an incremental cost per QALY within commonly accepted thresholds (reported ICER)
07
In a 2019 peer-reviewed analysis, antibiotic-resistant infections were associated with $1.0 billion in additional costs to the healthcare system over a study period (reported total incremental costs)
Interpretation
Cost Analysis Interpretation
Cost analyses consistently show that antimicrobial resistance substantially raises healthcare spending, with estimates rising by about $6,500 to $29,000 per case compared with non-resistant infections, while targeted prevention such as stewardship and infection control can cut modeled AMR-related costs by 15%.
08 · Category
Treatment & Prescribing1 stats
01
The global antibiotic consumption for human use was 64.4 defined daily doses (DDD) per 1,000 inhabitants per day in 2020 in the sample covered by the OECD/FAO/WHO monitoring framework (latest year in the dataset).
Interpretation
Treatment & Prescribing Interpretation
In 2020, global antibiotic consumption for human use sat at 64.4 defined daily doses per 1,000 inhabitants per day, underscoring how high the prescribing volume was for the Treatment and Prescribing side of antimicrobial resistance.
09 · Category
Prevalence & Resistance1 stats
01
410,000 deaths occurred among people with MDR/RR-TB in 2023 (estimated).
Interpretation
Prevalence & Resistance Interpretation
In the Prevalence and Resistance category, an estimated 410,000 deaths in 2023 among people with MDR or RR-TB underscore how seriously resistant tuberculosis continues to drive preventable mortality.
10 · Category
Outcomes & Economics5 stats
01
A meta-analysis of randomized trials found that antimicrobial stewardship reduced hospital mortality by 0.5% (relative measure reported across included studies).
02
A 2021 systematic review reported that antimicrobial stewardship programs were associated with reduced antibiotic consumption, with a pooled mean reduction of 19% across included studies (meta-analytic estimate).
03
In the US, AMR increases average length of stay by 2.9 days for hospitalized patients with resistant infections (claims-based analysis).
04
A 2020 peer-reviewed study estimated that antimicrobial-resistant infections add $13,000-$18,000 per case in direct healthcare costs (range reported across modeled scenarios).
05
In Europe, implementing infection prevention and control is estimated to avert 1 in 4 AMR-related deaths in hospitalized settings (modeled impact estimate).
Interpretation
Outcomes & Economics Interpretation
Across outcomes and economics, the evidence points to stewardship and prevention paying off, with stewardship cutting hospital mortality by 0.5% while AMR in the US lengthens stays by 2.9 days and resistant infections cost $13,000 to $18,000 more per case, and in Europe infection prevention and control is estimated to prevent 1 in 4 AMR-related hospital deaths.
11 · Category
Market & Investment5 stats
01
In 2022, the global antimicrobial susceptibility testing market size was $2.8 billion (and growing), per a published industry forecast.
02
In 2023, the global antimicrobial resistance diagnostics market was $3.2 billion (forecasted growth cited in market coverage).
03
From 2024 to 2030, the global antimicrobial susceptibility testing market is forecast to grow at a CAGR of 10.1% (market forecast).
04
From 2024 to 2030, the antimicrobial resistance diagnostics market is forecast to grow at a CAGR of 11.2% (market forecast).
05
The European market for antimicrobial susceptibility testing instruments was valued at €410 million in 2023 (industry estimate).
Interpretation
Market & Investment Interpretation
The “Market and Investment” outlook for antimicrobial resistance is clearly on an upswing, with the global antimicrobial susceptibility testing market rising from $2.8 billion in 2022 to an expected strong 10.1% CAGR from 2024 to 2030 and the antimicrobial resistance diagnostics market projected to grow even faster at 11.2% CAGR over the same period.
report visual · Key figures
Antimicrobial resistance burden and impact over time
AMR remains a major and growing health burden, with millions of deaths and large disease impact reported in recent estimates.
2019
In 2019, the analysis estimated 35.7 million AMR-associated DALYs due to bacterial resistance
1.27
WHO estimates that AMR caused 1.27 million deaths in 2019
35,000
In ECDC/EMA 2023 antimicrobial resistance surveillance report, 35,000 hospital bloodstream infections due to AMR organis
410,000
410,000 deaths occurred among people with MDR/RR-TB in 2023 (estimated).
source-verifiedthelancet.com · who.int · ecdc.europa.eu · worldhealthorg.shinyapps.io2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Antimicrobial Resistance Statistics. Gitnux. https://gitnux.org/antimicrobial-resistance-statistics
MLA
Henrik Dahl. "Antimicrobial Resistance Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/antimicrobial-resistance-statistics.
Chicago
Henrik Dahl. 2026. "Antimicrobial Resistance Statistics." Gitnux. https://gitnux.org/antimicrobial-resistance-statistics.
Sources & references
50 datasets cited across this report · attribution is report-level
+21 additional datasets cited (not shown individually)